MNPR

Company Overview — What Does Monopar Therapeutics Do?

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics (MNPR) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Chandler D. Robinson and employs approximately 10 people. With a market capitalization of $371M, MNPR is one of the notable companies in the Healthcare sector.

Monopar Therapeutics (MNPR) Stock Rating — Reduce (April 2026)

As of April 2026, Monopar Therapeutics receives a Reduce rating with a composite score of 33.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MNPR ranks #3,004 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Monopar Therapeutics ranks #435 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MNPR Stock Price and 52-Week Range

Monopar Therapeutics (MNPR) currently trades at $56.08. The stock lost $1.84 (3.2%) in the most recent trading session. The 52-week high for MNPR is $105.00, which means the stock is currently trading -46.6% from its annual peak. The 52-week low is $26.05, putting the stock 115.2% above its annual trough. Recent trading volume was 203K shares, suggesting relatively thin trading activity.

Is MNPR Overvalued or Undervalued? — Valuation Analysis

Monopar Therapeutics (MNPR) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.60x, versus the sector average of 2.75x.

At current multiples, Monopar Therapeutics trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Monopar Therapeutics Profitability — ROE, Margins, and Quality Score

Monopar Therapeutics (MNPR) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -7.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -7.0% versus the sector average of -33.1%.

Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MNPR Debt, Balance Sheet, and Financial Health

Monopar Therapeutics has a debt-to-equity ratio of 2.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 51.35x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $128M.

MNPR has a beta of 1.32, meaning it is more volatile than the broader market — a $10,000 investment in MNPR would be expected to move 31.8% more than the S&P 500 on any given day. The stability factor score for Monopar Therapeutics is 31/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Monopar Therapeutics Revenue and Earnings History — Quarterly Trend

In TTM 2026, Monopar Therapeutics reported revenue of $0 and earnings per share (EPS) of $-1.85. Net income for the quarter was $-10M. Operating income came in at $-12M.

In FY 2025, Monopar Therapeutics reported revenue of $0 and earnings per share (EPS) of $-1.85. Net income for the quarter was $-14M. Operating income came in at $-17M.

In Q3 2025, Monopar Therapeutics reported revenue of $0 and earnings per share (EPS) of $-0.48. Net income for the quarter was $-3M. Operating income came in at $-4M.

In Q2 2025, Monopar Therapeutics reported revenue of $0 and earnings per share (EPS) of $-0.35. Net income for the quarter was $-2M. Operating income came in at $-3M.

Over the past 8 quarters, Monopar Therapeutics has experienced revenue contraction from $73,475 to $0. Investors analyzing MNPR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MNPR Dividend Yield and Income Analysis

Monopar Therapeutics (MNPR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MNPR Momentum and Technical Analysis Profile

Monopar Therapeutics (MNPR) has a momentum factor score of 38/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 51/100 reflects moderate short selling activity.

MNPR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Monopar Therapeutics (MNPR) ranks #435 out of 838 stocks based on the Blank Capital composite score. This places MNPR in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MNPR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MNPR vs S&P 500 (SPY) comparison to assess how Monopar Therapeutics stacks up against the broader market across all factor dimensions.

MNPR Next Earnings Date

No upcoming earnings date has been announced for Monopar Therapeutics (MNPR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MNPR? — Investment Thesis Summary

The quantitative profile for Monopar Therapeutics suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 29/100 indicates premium valuation. Momentum is weak at 38/100, a headwind for near-term performance. High volatility (stability score 31/100) increases portfolio risk.

In summary, Monopar Therapeutics (MNPR) earns a Reduce rating with a composite score of 33.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MNPR stock.

Related Resources for MNPR Investors

Explore more research and tools: MNPR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MNPR head-to-head with peers: MNPR vs AZN, MNPR vs SLGL, MNPR vs VMD.